Clinical Trial

A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.
Protocol Amendment History 5 changes
notable Primary completion moved earlier: 2027-03-03 -> 2026-12-03 2026-06-10
minor Completion moved earlier: 2027-03-03 -> 2026-12-03 2026-06-10
critical Recruitment opened 2026-05-23
notable Primary completion pushed: 2026-09-21 -> 2027-03-03 2026-05-23
minor Completion pushed: 2026-09-21 -> 2027-03-03 2026-05-23
Trial Details
NCT Number NCT07517250
Lead Sponsor Novartis Pharmaceuticals
Conditions Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease
Enrollment 160 participants
Start Date 2026-03-15
Primary Completion 2026-12-03 (estimated)
Study Completion 2026-12-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-09